搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Archaeoglobus fulgidus Putative antitoxin VapB5 (vapB5) CSB-YP523184DOC
CSB-EP523184DOC
CSB-BP523184DOC
CSB-MP523184DOC
CSB-EP523184DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0303 (AF_0303), partial CSB-YP523185DOC1
CSB-EP523185DOC1
CSB-BP523185DOC1
CSB-MP523185DOC1
CSB-EP523185DOC1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Probable adenylyl-sulfate kinase (cysC) CSB-YP523186DOC
CSB-EP523186DOC
CSB-BP523186DOC
CSB-MP523186DOC
CSB-EP523186DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0268 (AF_0268) CSB-YP523187DOC
CSB-EP523187DOC
CSB-BP523187DOC
CSB-MP523187DOC
CSB-EP523187DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0255 (AF_0255) CSB-YP523188DOC
CSB-EP523188DOC
CSB-BP523188DOC
CSB-MP523188DOC
CSB-EP523188DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0250 (AF_0250) CSB-YP523189DOC
CSB-EP523189DOC
CSB-BP523189DOC
CSB-MP523189DOC
CSB-EP523189DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0236 (AF_0236), partial CSB-YP523190DOC
CSB-EP523190DOC
CSB-BP523190DOC
CSB-MP523190DOC
CSB-EP523190DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus 3-dehydroquinate synthase (AF_0229) CSB-YP523191DOC
CSB-EP523191DOC
CSB-BP523191DOC
CSB-MP523191DOC
CSB-EP523191DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Probable 2-isopropylmalate synthase (leuA), partial CSB-YP523192DOC
CSB-EP523192DOC
CSB-BP523192DOC
CSB-MP523192DOC
CSB-EP523192DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus DNA-directed RNA polymerase subunit L (rpoL) CSB-YP523193DOC
CSB-EP523193DOC
CSB-BP523193DOC
CSB-MP523193DOC
CSB-EP523193DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus O-phospho-L-seryl-tRNA:Cys-tRNA synthase 2 (AF_0181) CSB-YP523194DOC
CSB-EP523194DOC
CSB-BP523194DOC
CSB-MP523194DOC
CSB-EP523194DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0155 (AF_0155) CSB-YP523195DOC
CSB-EP523195DOC
CSB-BP523195DOC
CSB-MP523195DOC
CSB-EP523195DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0150 (AF_0150) CSB-YP523196DOC
CSB-EP523196DOC
CSB-BP523196DOC
CSB-MP523196DOC
CSB-EP523196DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0136 (AF_0136) CSB-YP523197DOC
CSB-EP523197DOC
CSB-BP523197DOC
CSB-MP523197DOC
CSB-EP523197DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0118 (AF_0118) CSB-YP523198DOC
CSB-EP523198DOC
CSB-BP523198DOC
CSB-MP523198DOC
CSB-EP523198DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus O-phosphoserine--tRNA (Cys) ligase, partial CSB-YP523199DOC
CSB-EP523199DOC
CSB-BP523199DOC
CSB-MP523199DOC
CSB-EP523199DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Aspartate carbamoyltransferase (pyrB) CSB-YP523200DOC
CSB-EP523200DOC
CSB-BP523200DOC
CSB-MP523200DOC
CSB-EP523200DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0097 (AF_0097), partial CSB-YP523201DOC1
CSB-EP523201DOC1
CSB-BP523201DOC1
CSB-MP523201DOC1
CSB-EP523201DOC1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Molybdate/tungstate import ATP-binding protein WtpC (wtpC) CSB-YP523202DOC
CSB-EP523202DOC
CSB-BP523202DOC
CSB-MP523202DOC
CSB-EP523202DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_0073 (AF_0073) CSB-YP523203DOC
CSB-EP523203DOC
CSB-BP523203DOC
CSB-MP523203DOC
CSB-EP523203DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>